Spyridon Champeris Tsaniras

Dr. Spyridon Champeris Tsaniras

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Trends in Biochemical Sciences
Verified
Journal Article
Closed access
MPMichalis Petropoulos
Michalis Petropoulos
STSpyridon Champeris Tsaniras
Spyridon Champeris Tsaniras
Stavros TaravirasStavros Taraviras
Stavros Taraviras
ZLZoi Lygerou
Zoi Lygerou

1 April 2018 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
KKKonstantina Kaplani
Konstantina Kaplani
SKStamatina Koutsi
Stamatina Koutsi
VAVasileios Armenis
Vasileios Armenis
FSFoteini G. Skondra
Foteini G. Skondra
NKNikolaos Karantzelis
Nikolaos Karantzelis
Stavros TaravirasStavros Taraviras
Stavros Taraviras

1 June 2014 in Seminars in Cell & Developmental Biology
Verified
Journal Article
Open access
STSpyridon Champeris Tsaniras
Spyridon Champeris Tsaniras
NKN. Kanellakis
N. Kanellakis
ISI.E. Symeonidou
I.E. Symeonidou
PNPinelopi Nikolopoulou
Pinelopi Nikolopoulou
ZLZ. Lygerou
Z. Lygerou
Stavros TaravirasStavros Taraviras
Stavros Taraviras
Recent findings provide evidence for a functional interplay between DNA replication and the seemingly distinct areas of cancer, development and pluripotency. Protein complexes participating in DNA replication origin licensing are now known to have roles in development, while their deregulation can lead to cancer. Moreover, transcription factors implicated in the maintenance of or reversal to the pluripotent state have links to the pre-replicative machinery. Several studies have shown that overexpression of these factors is associated to cancer.

10 March 2018 in Cancer Genomics & Proteomics
Verified
Journal Article
Open access
PDF file
DTDimitrios Tsoumas
Dimitrios Tsoumas
SNSofia Nikou
Sofia Nikou
EGEfstathia Giannopoulou
Efstathia Giannopoulou
STSpyridon Champeris Tsaniras
Spyridon Champeris Tsaniras
CSChaido Sirinian
Chaido Sirinian
VBVasiliki Bravou
Vasiliki Bravou
Background/Aim: Epithelial-mesenchymal transition (EMT) and cancer stem cells (CSC) are critically implicated in cancer metastasis and chemoresistance. Herein, we investigated integrin-linked kinase (ILK)'s role in human colon cancer (CRC) progression and chemoresistance in relation to EMT and CSC markers. Patients and Methods: Expression of ILK, EMT and CSC markers were evaluated by immunohistochemistry in 149 CRC samples. We also generated colon cancer cells resistant to 5-FU and oxaliplatin and studied the effect of ILK inhibition on drug response by MTT assay and on EMT and CSC markers' expression. Results: ILK expression in human CRC correlates with EMT and CSC markers and is associated with metastasis and chemoresistance. ILK inhibition increases sensitivity of resistant cells to 5-FU and oxaliplatin and reduces the levels of EMT and CSC markers in 5-FU resistant cells. Conclusion: ILK overexpression in human CRC associates with EMT and CSC traits, contributing to tumor progression and chemoresistance.

12 April 2010 in Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
STSpyridon Champeris Tsaniras
Spyridon Champeris Tsaniras
PJPeter Martin Jones
Peter Martin Jones
Type 1 diabetes results from an insufficiency of insulin production as a result of autoimmune destruction of the insulin-secreting pancreatic β-cells. It can be treated by transplantation of islets of Langerhans from human donors, but widespread application of this therapy is restricted by the scarcity of donor tissue. Generation of functional β-cells from embryonic stem (ES) cells in vitro could provide a source of an alternative graft material. Several ES cell differentiation protocols have reported the production of insulin-producing cells by mimicking the in vivo developmental stages of pancreatic organogenesis in which cells are transitioned through mesendoderm, definitive endoderm, foregut endoderm, pancreatic endoderm, and the endocrine precursor stage, until mature β-cells are obtained. These studies provide proof of concept that recapitulating pancreatic development in vitro offers a useful strategy for generating β-cells, but current differentiation protocols employ a bewildering variety of growth factors, mitogens, and pharmacological agents. In this review, we will attempt to clarify the functions of these agents in in vitro differentiation strategies by focusing on the intracellular signaling pathways through which they operate – phosphatidylinositol 3-kinase, transforming growth factor β, Wnt/β-catenin, Hedgehog, and Notch.

21 August 2018 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
STSpyridon Champeris Tsaniras
Spyridon Champeris Tsaniras
MVMaria Villiou
Maria Villiou
AGAnastassios D Giannou
Anastassios D Giannou
SNSofia Nikou
Sofia Nikou
MPMichalis Petropoulos
Michalis Petropoulos
Stavros TaravirasStavros Taraviras
Stavros Taraviras